Technological risks in drug development
Potential for insufficient efficacy or intolerable side effects.
- Materiality
- high
Cantargia
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases. The company's innovative approach centers around the IL1RAP molecule, which is found on cancer cells and is involved in disease-causing inflammation. Cantargia's drug candidates, such as Nadunolimab and CAN10, aim to provide new treatment options for serious and debilitating diseases. The company operates primarily through strategic partnerships and has a strong intellectual property portfolio with over 100 patents globally.
22
9.80
9.67
| % | |
|---|---|
| Cancer Therapies | 50% Includes drugs targeting cancer cells, such as Nadunolimab. |
| Autoimmune and Inflammatory Therapies | 30% Includes treatments like CAN10 for autoimmune diseases. |
| Strategic Partnerships | 20% Collaborations for drug development and commercialization. |
Cantargia's customers primarily include pharmaceutical companies and healthcare providers seeking advanced treatments...
- Pharmaceutical Companiesprimary
They partner with Cantargia for innovative drug development.
- Healthcare Providerssecondary
They use Cantargia's therapies to treat cancer and autoimmune diseases.
- Strategic Partnersemerging
They collaborate on drug development and commercialization.
Cantargia is headquartered in Lund, Sweden, and operates primarily through partnerships with global pharmaceutical...
- •Headquartered in Lund, Sweden
- •Significant revenue from partnership with Otsuka in Japan
- •Focus on international collaborations for market access
- •Expanding reach in key oncology and immunology markets
Cantargia's strategic priorities include advancing its pipeline of antibody-based therapies, particularly Nadunolimab...
01
Advance Nadunolimab and CAN10medium-term
To achieve market registration and address unmet medical needs.
02
Leverage strategic partnershipsshort-term
To expand global market access and enhance drug development.
03
Maintain strong IP portfoliolong-term
To protect innovations and create competitive barriers.
Cantargia faces significant risks inherent in the biotech industry, including the high cost and uncertainty of drug...
Regulatory challenges
Need for successful clinical trials and approvals.
- Materiality
- high
Reliance on strategic partnerships
Dependency on partners for milestone achievements and commercialization.
- Materiality
- medium
Revenue recognition from milestone payments
high
Foreign exchange rate changes
medium
BioArctic
BIOA-B.ST · Health Care
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for severe neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS.
Hansa Biopharma
HNSA.ST · Health Care
Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions.
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
Janux Therapeutics, Inc.
JANX · Pharmaceutical Preparations
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its proprietary TRACTr, TRACIr, and ARM platforms.
NEKTAR THERAPEUTICS
NKTR · Pharmaceutical Preparations
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunotherapy medicines for autoimmune disease and cancer.
Edesa Biotech, Inc.
EDSA · Pharmaceutical Preparations
: 11/08/2026